|
IBTK expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.5310999679794E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.26499999761631E-08 |
| Normal-vs-Stage2 |
1.918930E-03 |
| Normal-vs-Stage3 |
1.37069999794903E-08 |
| Normal-vs-Stage4 |
1.38110001213221E-09 |
| Stage1-vs-Stage2 |
3.182000E-01 |
| Stage1-vs-Stage3 |
1.894000E-01 |
| Stage1-vs-Stage4 |
2.986100E-02 |
| Stage2-vs-Stage3 |
8.787900E-02 |
| Stage2-vs-Stage4 |
1.757880E-02 |
| Stage3-vs-Stage4 |
2.896600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.49909989871833E-10 |
| Normal-vs-AfricanAmerican |
1.439610E-02 |
| Normal-vs-Asian |
2.08440000037946E-07 |
| Caucasian-vs-AfricanAmerican |
1.284650E-01 |
| Caucasian-vs-Asian |
7.752200E-01 |
| AfricanAmerican-vs-Asian |
1.191640E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.72850000160707E-08 |
| Normal-vs-Female |
1.15120000199198E-08 |
| Male-vs-Female |
6.466400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.51800000020219E-07 |
| Normal-vs-Age(41-60Yrs) |
8.22409995659967E-09 |
| Normal-vs-Age(61-80Yrs) |
5.02170000027391E-08 |
| Normal-vs-Age(81-100Yrs) |
3.660600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.229200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.202000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.459200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.963800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.170400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.294600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.547360E-01 |
| Classical-VS-Follicular |
1.128960E-01 |
| Classical-VS-Other |
3.913000E-01 |
| Classical-VS-Normal |
4.43320002929681E-09 |
| Tall-VS-Follicular |
1.820410E-02 |
| Tall-VS-Other |
8.974000E-01 |
| Tall-VS-Normal |
6.21320000004921E-07 |
| Follicular-VS-Other |
2.456000E-01 |
| Follicular-VS-Normal |
2.156300E-03 |
| Other-VS-Normal |
2.963200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.91309999952871E-07 |
| Normal-vs-N1 |
4.03190003606113E-09 |
| N0-vs-N1 |
9.560100E-02 |
|
|
